Investigation of potential adverse central nervous system effects after long term oral administration of gadolinium in mice.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
    • Abstract:
      Objectives: To examine potential gadolinium (Gd) accumulation in the brain of healthy mice after long-term oral administration of Gd-containing food pellets and to investigate whether Gd leads to adverse central nervous system (CNS) effects, specifically focussing on locomotor impairment in Gd exposed compared to control animals.
      Materials and Methods: The local Animal Experimental Ethics Committee approved all procedures and applications. Fifteen female C57Bl/6 mice were orally exposed to a daily intake of 0.57 mmol Gd chloride/ kg body weight over a period of 90 weeks from the age of 4 weeks on. Gd-free, but otherwise equivalent experimental diets were given to the control group (N = 13). The animals were monitored daily by animal caretakers regarding any visible signs of distress and evaluated clinically every four weeks for the first 60 weeks and afterwards every two weeks for a better temporal resolution of potential long-term effects regarding impairment of motor performance and loss of body weight. The individual Gd content was measured using mass spectrometry in a sub-cohort of N = 6 mice.
      Results: The absolute brain Gd levels of the Gd-exposed mice were significantly increased compared to control mice (0.033± 0.009 vs. 0.006± 0.002 nmol Gd/ g brain tissue). Long-term oral Gd exposure over almost the entire life-span did not lead to adverse CNS effects including locomotor changes (rotarod performance, p = 0.1467) in healthy mice throughout the study period. Gd-exposed mice showed less increased body weight compared to control mice during the study period (p = 0.0423). Histopathological alterations, such as hepatocellular vacuolization due to fatty change in the liver and a loss of nucleated cells in the red pulp of the spleen, were found in peripheral organs of both groups.
      Conclusions: Low levels of intracerebral Gd caused by chronic oral exposure over almost the entire life span of mice did not lead to alterations in locomotor abilities in healthy mice throughout the normal aging process.
      Competing Interests: T.F. und H.P. are employees of Bayer AG and are currently conducting research sponsored by this company. For our study, T.F. and H.P. contributed primarily to the methodology of intracerebral Gd measurements by ICP-MS. The research is, however, not financially supported by industry. The commercial affiliation to Bayer AG does not alter our adherence to PLOS ONE policies on sharing data and materials.
    • References:
      Radiology. 2014 Mar;270(3):834-41. (PMID: 24475844)
      Invest Radiol. 2015 Aug;50(8):473-80. (PMID: 26107651)
      Lancet. 2000 Sep 16;356(9234):1000-1. (PMID: 11041404)
      Nephrol Dial Transplant. 2006 Apr;21(4):1104-8. (PMID: 16431890)
      Mar Pollut Bull. 2010 Jul;60(7):1113-6. (PMID: 20409563)
      Radiology. 2015 Jul;276(1):228-32. (PMID: 25942417)
      AJNR Am J Neuroradiol. 2015 Oct;36(10):1859-65. (PMID: 26294649)
      Hum Exp Toxicol. 1998 Nov;17(11):633-7. (PMID: 9865421)
      Invest Radiol. 2018 Feb;53(2):110-118. (PMID: 28915162)
      Anal Chem. 2015 Mar 17;87(6):3321-8. (PMID: 25708271)
      Invest Radiol. 2016 Feb;51(2):73-82. (PMID: 26606549)
      Neurol Neuroimmunol Neuroinflamm. 2018 Oct 19;6(1):e515. (PMID: 30568993)
      Acta Neuropathol. 2013 Jun;125(6):795-813. (PMID: 23604588)
      Int J Radiat Biol. 2014 Nov;90(11):996-1010. (PMID: 24475737)
      Br J Pharmacol Chemother. 1961 Dec;17:526-32. (PMID: 13903826)
      Environ Sci Technol. 2016 Apr 19;50(8):4159-68. (PMID: 26742888)
      Radiology. 2015 Sep;276(3):836-44. (PMID: 26079490)
      J Magn Reson Imaging. 1999 Sep;10(3):477-84. (PMID: 10508312)
      Radiology. 2015 Jun;275(3):783-91. (PMID: 25848905)
      Invest Radiol. 2017 Jun;52(6):324-333. (PMID: 28323657)
      Invest Radiol. 2016 Jul;51(7):447-53. (PMID: 26863577)
      Acta Neuropathol. 2018 Jul;136(1):127-138. (PMID: 29748901)
      Science. 2000 Feb 18;287(5456):1265-9. (PMID: 10678833)
      Eur Radiol. 2016 Mar;26(3):807-15. (PMID: 26105022)
      Eur Radiol. 2009 Jun;19(6):1417-24. (PMID: 19169690)
      Radiology. 2015 Jun;275(3):803-9. (PMID: 25633504)
      Invest Radiol. 2014 Oct;49(10):685-90. (PMID: 24872007)
      ACS Appl Mater Interfaces. 2017 Feb 22;9(7):5784-5792. (PMID: 28118705)
      Jpn J Radiol. 2016 Jan;34(1):3-9. (PMID: 26608061)
      Food Cosmet Toxicol. 1980 Oct;18(5):517-22. (PMID: 7203299)
      Radiology. 2015 Jun;275(3):772-82. (PMID: 25742194)
      Invest Radiol. 2015 Nov;50(11):743-8. (PMID: 26352749)
      Adv Chronic Kidney Dis. 2017 May;24(3):138-146. (PMID: 28501075)
      Invest Radiol. 2016 Oct;51(10):655-60. (PMID: 27299580)
      Brain Dev. 2016 Mar;38(3):331-6. (PMID: 26345358)
      Pediatrics. 2015 Dec;136(6):e1637-40. (PMID: 26574593)
      J Magn Reson Imaging. 2012 Nov;36(5):1060-71. (PMID: 23090917)
      Radiology. 2007 Apr;243(1):148-57. (PMID: 17267695)
      Crit Rev Toxicol. 2014 Nov;44(10):895-913. (PMID: 25257840)
      AJR Am J Roentgenol. 2016 Feb;206(2):414-9. (PMID: 26700156)
      Radiology. 2017 Mar;282(3):743-751. (PMID: 27673510)
      J Magn Reson Imaging. 2007 Nov;26(5):1190-7. (PMID: 17969161)
      J Environ Pathol Toxicol Oncol. 1995;14(1):1-9. (PMID: 7473067)
      Magn Reson Imaging. 1987;5(3):221-31. (PMID: 3626790)
      Cardiovasc Drug Rev. 2001 Spring;19(1):41-56. (PMID: 11314600)
      Toxicol Pathol. 1997 May-Jun;25(3):245-55. (PMID: 9210255)
      Invest Radiol. 2015 Jul;50(7):470-2. (PMID: 25756685)
      Acta Neuropathol. 2014 May;127(5):779-80. (PMID: 24615514)
      Invest Radiol. 2016 Feb;51(2):83-9. (PMID: 26606548)
      Exp Toxicol Pathol. 2007 Apr;58(5):323-30. (PMID: 17150343)
    • Accession Number:
      AU0V1LM3JT (Gadolinium)
    • Publication Date:
      Date Created: 20200424 Date Completed: 20200713 Latest Revision: 20200713
    • Publication Date:
      20240105
    • Accession Number:
      PMC7179865
    • Accession Number:
      10.1371/journal.pone.0231495
    • Accession Number:
      32324769